Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.81 |
| ▸ | HTR2C | P28335 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | HRH1 | P35367 | 2/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.81 |
| ▸ | DRD3 | P35462 | 2/20 | 0.81 |
| ▸ | HTR2B | P41595 | 2/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | ACHE | P22303 | 1/20 | 0.81 |
| ▸ | HRH2 | P25021 | 1/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Escitalopram SCHEMBL34948 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL3858802 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL29494157 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL29414626 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL13235283 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL29358316 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL946 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2811554 | 0.89 | SLC6A4 (0.81) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1515377 | 0.89 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL21820669 | 0.89 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279487-B1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2026-04-29 | — | — | EP | claimed |
| CN-116635375-B | Purification method of citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20240390376-A1 | METHOD FOR PREVENTING ADVERSE PREGNANCY OUTCOMES DUE TO USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) DURING GESTATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-11-28 | — | — | US | claimed |
| US-20240300911-A1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2024-09-12 | — | — | US | claimed |
| EP-4279487-A1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2023-11-22 | — | — | EP | claimed |
| CN-116635375-A | Purification method of citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | claimed |
| CN-113105419-B | Method for preparing S-citalopram from R-diol | 山东新华制药股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2022152078-A1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | 浙江华海药业股份有限公司 | 2022-07-21 | — | — | WO | claimed |
| CN-114763343-A | Method for purifying citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| EP-4279487-B1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4279487-B1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| CN-121673197-A | Chiral synthesis method of S-citalopram intermediate | 诚弘制药(威海)有限责任公司 | 2026-03-17 | — | — | CN | disclosed |
| CN-121673197-A | Chiral synthesis method of S-citalopram intermediate | 诚弘制药(威海)有限责任公司 | 2026-03-17 | — | — | CN | disclosed |
| CN-114763343-B | Purification method of citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2026-02-10 | — | — | CN | disclosed |
| CN-114763343-A | Method for purifying citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-114685409-A | Escitalopram derivative, immunogen, anti-escitalopram specific antibody, preparation method and application thereof | 苏州博源医疗科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109988083-B | Preparation method of high-optical-purity escitalopram oxalate intermediate S-configuration diol | 北京哈三联科技有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-107074750-B | Method for splitting citalopram intermediate 5-cyanodiol | 浙江华海药业股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390376-A1 | METHOD FOR PREVENTING ADVERSE PREGNANCY OUTCOMES DUE TO USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) DURING GESTATION | SLC6A4, SLC6A2, TPH1 | SLC6A4 1/4885SLC6A2 2/4885HTR2C 22/4885 |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CACNA1G, CACNA1I, CACNA1H | SLC6A4 98/4885SLC6A2 94/4885HTR2C 290/4885 |
| US-20240300911-A1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | SLC6A4, SLC6A2, SI | SLC6A4 1/4885SLC6A2 2/4885HTR2C 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.